ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1
Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity
Abstract Number: 2
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Abstract Number: 3
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Abstract Number: 4
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Abstract Number: 5
Plasma Levels Of PF-4var/CXCL4L1, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS)
Abstract Number: 6
Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome
Abstract Number: 7
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Abstract Number: 8
Clinical Evaluation Of Two Anti-Beta2glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Abstract Number: 9
Domain 1 Is The Main Specificity Of Anti-β2glycoprotein I Antibodies In Systemic Autoimmune Diseases
Abstract Number: 10
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Abstract Number: 11
Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 441 Patients From The “CAPS Registry”
Abstract Number: 12
Phosphatidiyserine-Prothrombin Complex (aPS/PT) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome
Abstract Number: 13
A MORE Specific Immunoassay For The Diagnosis Of APS
Abstract Number: 14
Isotype Dependent Performance Of Beta2glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Abstract Number: 15
Establishment Of Standardized International Units For IgM ANTI-β2glycoprotein Antibody Measurement
Abstract Number: 16
Only IgG and IgA β2glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 17
Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases
Abstract Number: 18
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Abstract Number: 19
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Abstract Number: 20
Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 21
Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS
Abstract Number: 22
WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome?
Abstract Number: 23
Seizures In Systemic Lupus Erythematosus Are Not An Inflammatory Manifestation Of Lupus Anticoagulant

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology